Skip to main navigation Skip to search Skip to main content

Targeting the C-terminal focal adhesion kinase scaffold in pancreatic cancer

  • Priyanka N. Gogate
  • , Elena V. Kurenova
  • , Manivannan Ethirajan
  • , Jianqun Liao
  • , Michael Yemma
  • , Arindam Sen
  • , Ravindra K. Pandey
  • , William G. Cance
  • Roswell Park Cancer Institute
  • CureFAKtor Pharmaceuticals

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

Preliminary studies in our laboratory have demonstrated the importance of both the NH2 and COOH terminus scaffolding functions of focal adhesion kinase (FAK). Here, we describe a new small molecule inhibitor, C10, that targets the FAK C-terminus scaffold. C10 showed marked selectivity for cells overexpressing VEGFR3 when tested in isogenic cell lines, MCF7 and MCF7-VEGFR3. C10 preferentially inhibited pancreatic tumor growth in vivo in cells with high FAK-Y925 and VEGFR3 expression. Treatment with C10 led to a significant inhibition in endothelial cell proliferation and tumor endothelial and lymphatic vessel density and decrease in interstitial fluid pressure. These results highlight the underlying importance of targeting the FAK scaffold to treat human cancers.

Original languageEnglish
Pages (from-to)281-289
Number of pages9
JournalCancer Letters
Volume353
Issue number2
DOIs
StatePublished - 2014

Keywords

  • FAK scaffold inhibition
  • Focal adhesion kinase
  • Focal adhesion targeting domain
  • Pancreatic cancer
  • Vascular endothelial growth factor receptor-3

Fingerprint

Dive into the research topics of 'Targeting the C-terminal focal adhesion kinase scaffold in pancreatic cancer'. Together they form a unique fingerprint.

Cite this